Category Archives: Non-U.S. Practice

Patenting “Natural Products” Down-Under Post-Myriad

Although the Australian High Court held that claims to naturally occurring DNA (e.g., BRCA1 nucleic acid) were not patent eligible because they were not a “manner of manufacture,” since the encoded information therein was not “made” by human action, in … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , | 1 Comment

A Hidden Danger Under The EPC – The “Extension Trap”

Provided to us by Dr. Stefan Danner of DHS Patentanwalts GmbH, find below the current issue of the biotech IP newsletter dealing with recent EPO case law on Article 123(2)(3) EPC. Extension Trap

Posted in Non-U.S. Practice | Tagged , , , | Leave a comment

Biotech IP Newsletters

Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy  

Posted in Non-U.S. Practice | Tagged , , , , | Leave a comment

One step ahead and one step backward for the EU patent

The following is a contribution from Camilla Rendal Nielsen of Zacco Denmark A/S 1.   The EU Competiveness Council have authorised “enhanced cooperation” in the area of unitary patent protection, and. 2.   The EU court now states that the proposed Patents Court … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , | Leave a comment